blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3833759

EP3833759 - METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  03.12.2025
Database last updated on 28.03.2026
FormerExamination is in progress
Status updated on  29.09.2023
FormerRequest for examination was made
Status updated on  14.05.2021
FormerThe international publication has been made
Status updated on  15.02.2020
Formerunknown
Status updated on  28.09.2019
Most recent event   Tooltip03.12.2025New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Juno Therapeutics, Inc.
400 Dexter Ave. N, Suite 1200
Seattle, WA 98109 / US
[2021/24]
Inventor(s)01 / BRIGGS, Adrian Wrangham
400 Dexter Ave. N, Suite 1200
Seattle, Washington 98109 / US
 [2021/24]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2021/24]Goodfellow, Hugh Robin
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date19770209.509.08.2019
[2021/24]
WO2019US46048
Priority number, dateUS201862716972P09.08.2018         Original published format: US 201862716972 P
[2021/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020033916
Date:13.02.2020
Language:EN
[2020/07]
Type: A1 Application with search report 
No.:EP3833759
Date:16.06.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 13.02.2020 takes the place of the publication of the European patent application.
[2021/24]
Search report(s)International search report - published on:EP13.02.2020
ClassificationIPC:C12N15/10, C12Q1/6806
[2021/24]
CPC:
C12Q1/6806 (EP,IL,KR); C12Q1/686 (KR,US); A61K40/11 (EP,IL,KR,US);
A61K40/31 (EP,IL,KR,US); A61K40/4215 (EP,IL,KR,US); C07K14/7051 (EP,KR);
C07K14/70521 (KR); C07K14/70578 (KR); C12N15/90 (KR,US);
C12Q1/70 (US); C07K2319/02 (KR); C07K2319/03 (EP,KR);
C12N2750/14143 (KR,US); C12Q2537/16 (KR); C12Q2545/101 (KR);
C12Q2563/159 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/24]
Extension statesBA11.02.2021
ME11.02.2021
Validation statesKH11.02.2021
MA11.02.2021
MD11.02.2021
TN11.02.2021
TitleGerman:VERFAHREN ZUR BEWERTUNG INTEGRIERTER NUKLEINSÄUREN[2021/24]
English:METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS[2021/24]
French:PROCÉDÉS POUR ÉVALUER DES ACIDES NUCLÉIQUES INTÉGRÉS[2021/24]
Entry into regional phase11.02.2021National basic fee paid 
11.02.2021Designation fee(s) paid 
11.02.2021Examination fee paid 
Examination procedure11.02.2021Examination requested  [2021/24]
11.02.2021Date on which the examining division has become responsible
27.09.2021Amendment by applicant (claims and/or description)
04.10.2023Despatch of a communication from the examining division (Time limit: M04)
14.02.2024Reply to a communication from the examining division
03.12.2025Communication of intention to grant the patent
Fees paidRenewal fee
13.08.2021Renewal fee patent year 03
15.07.2022Renewal fee patent year 04
05.07.2023Renewal fee patent year 05
04.07.2024Renewal fee patent year 06
03.07.2025Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]   MARIA P. SERRA ET AL: "Modulation of oat arginine decarboxylase gene expression and genome organization in transgenic Trypanosoma cruzi epimastigotes", FEBS JOURNAL, vol. 273, no. 3, 1 February 2006 (2006-02-01), GB, pages 628 - 637, XP055632693, ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2005.05098.x

DOI:   http://dx.doi.org/10.1111/j.1742-4658.2005.05098.x
 [XI]   YE GUANG-NING ET AL: "TOBACCO (NICOTIANA TABACUM) NUCLEAR TRANSGENICS WITH HIGH COPY NUMBER CAN EXPRESS NPTII DRIVEN BY THE CHLOROPLAST PSBA PROMOTER", PLANT CELL REPORTS, SPRINGER, BERLIN/HEIDELBERG, vol. 15, no. 7, 1 January 1996 (1996-01-01), pages 479 - 483, XP009079842, ISSN: 0721-7714, DOI: 10.1007/S002990050058

DOI:   http://dx.doi.org/10.1007/s002990050058
by applicantUS9599590
 US2017240882
 US2017254774
 US4835263
 US5801115
 WO2009072003
 US2011003380
 WO2016073602
 WO2015164675
 US2017037369
 US4452773
 EP0452342
 US4795698
 US5200084
 US6040177
 WO2014055668
 US7446190
 WO9208796
 WO9428143
 US6123655
 US6733433
 US2008171951
 WO0038762
 US5219740
 US6207453
 US8802374
 US6060273
 WO2014031687
 US2007116690
 WO0014257
 WO2013126726
 WO2012129514
 WO2013166321
 WO2013071154
 WO2013123061
 US2002131960
 US2013287748
 US2013149337
 US6451995
 US8252592
 US8339645
 US8398282
 US7446179
 US6410319
 US7070995
 US7265209
 US7354762
 US7446191
 US8324353
 US8479118
 EP2537416
 US8389282
 WO2016090320
 WO2016090327
 WO2010104949
 WO2017173256
 WO2016090329
 WO2016090312
 US2002150914
 US2003223994
 US2004191260
 US2006034850
 US2007092530
 US2009226474
 US2009304679
 WO03068201
 US2014294841
 US8822647
 US2014271635
 US8911993
 WO03020763
 WO2004033685
 WO2011044186
 WO9613593
 WO9618105
 WO9960120
 WO9918129
 WO2006000830
 US2017051035
 US2003170238
 US4690915
 US8153765
 US8603477
 US8008450
 US2012189622
 US2010260748
 WO2006099875
 WO2009080829
 WO2012092612
 WO2014210064
 US5087616
   POHL ET AL., EXPERT REV. MOL. DIAGN., vol. 4, no. 1, 2004, pages 41 - 47
   HUGGETT ET AL., CLINICAL CHEMISTRY, vol. 59, 2013, pages 1691 - 1693
   SHUGA ET AL., NUCLEIC ACIDS RESEARCH, vol. 41, no. 16, 2013, pages el59
   WHALE ET AL., PLOS ONE, vol. 3, 2013, pages e58177
   HINDSON ET AL., ANAL CHEM, vol. 83, no. 22, 2011, pages 8604 - 8610
   PINHEIRO ET AL., ANAL CHEM, vol. 84, 2012, pages 1003 - 1011
   CHARRIER ET AL., GENE THERAPY, vol. 18, 2011, pages 479 - 487
   CHRISTODOULOU ET AL., GENE THERAPY, vol. 23, 2016, pages 113 - 118
   ZHAO ET AL., HUMAN GENE THERAPY METHODS, vol. 28, no. 4, 2017, pages 205 - 214
   MILONE ET AL., MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, vol. 8, 2018, pages 210 - 221
   BRENTJENS ET AL., SCI TRANSL MED., vol. 5, no. 177, 2013
   PARK ET AL., MOLECULAR THERAPY, vol. 15, no. 4, 2007, pages 825 - 833
   SAVOLDO ET AL., JCI, vol. 121, no. 5, 2011, pages 1822 - 1826
   CHICAYBAM ET AL., PLOS ONE, vol. 8, no. 3, 2013, pages e60298
   DAVILA ET AL., ONCOIMMUNOLOGY, vol. 1, no. 9, 2012, pages 1577 - 1583
   BRENTJENS ET AL., BLOOD, vol. 118, no. 18, 2011, pages 4817 - 4828
   JENSEN ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 16, no. 9, September 2010 (2010-09-01), pages 1245 - 1256
   TERAKURA ET AL., BLOOD, vol. 1, 2012, pages 72 - 82
   KLEBANOFF ET AL., J IMMUNOTHER., vol. 35, no. 9, 2012, pages 651 - 660
   METHODS IN MOLECULAR MEDICINE, vol. 58
   "Cell Behavior In Vitro and In Vivo", vol. 2, HUMANA PRESS INC., article "Metastasis Research Protocols", pages: 17 - 25
   LEE ET AL., NANO LETT, vol. 12, 2012, pages 6322 - 27
   VAN TEDELOO ET AL., GENE THERAPY, vol. 7, no. 16, 2000, pages 1431 - 1437
   MANURI ET AL., HUM GENE THER, vol. 21, no. 4, 2010, pages 427 - 437
   SHARMA ET AL., MOLEC THER NUCL ACIDS, vol. 2, 2013, pages e74
   HUANG ET AL., METHODS MOL BIOL, vol. 506, 2009, pages 115 - 126
   JOHNSTON, NATURE, vol. 346, 1990, pages 776 - 777
   BRASH ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 2031 - 2034
   CHEADLE ET AL.: "Chimeric antigen receptors for T-cell based therapy", METHODS MOL BIOL., vol. 907, 2012, pages 645 - 66, XP009179541, doi:10.1007/978-1-61779-974-7_36

DOI:   http://dx.doi.org/10.1007/978-1-61779-974-7_36
   BARRETT ET AL., CHIMERIC ANTIGEN RECEPTOR THERAPY FOR CANCER ANNUAL REVIEW OF MEDICINE, vol. 65, 2014, pages 333 - 347
   LUPTON S. D. ET AL., MOL. AND CELL BIOL., vol. 11, no. 6, 1991, pages 6
   RIDDELL ET AL., HUMAN GENE THERAPY, vol. 3, 1992, pages 319 - 338
   KOSTE ET AL., GENE THERAPY, 3 April 2014 (2014-04-03)
   CARLENS ET AL., EXP HEMATOL, vol. 28, no. 10, 2000, pages 1137 - 46
   ALONSO-CAMINO ET AL., MOL THER NUCL ACIDS, vol. 2, 2013, pages e93
   PARK ET AL., TRENDS BIOTECHNOL., vol. 29, no. 11, November 2011 (2011-11-01), pages 550 - 557
   MILLERROSMAN, BIOTECHNIQUES, vol. 7, 1989, pages 980 - 990
   MILLER, A. D., HUMAN GENE THERAPY, vol. 1, 1990, pages 5 - 14
   SCARPA ET AL., VIROLOGY, vol. 180, 1991, pages 849 - 852
   BURNS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8033 - 8037
   BORIS-LAWRIETEMIN, CUR. OPIN. GENET. DEVELOP., vol. 3, 1993, pages 102 - 109
   WANG ET AL., J. IMMUNOTHER., vol. 35, no. 9, 2012, pages 689 - 701
   CAVALIERI ET AL., BLOOD, vol. 102, no. 2, 2003, pages 1637 - 1644
   VERHOEYEN ET AL., METHODS MOL BIOL., vol. 506, 2009, pages 97 - 114
   BAUM ET AL., MOLECULAR THERAPY: THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 13, 2006, pages 1050 - 1063
   HACKETT ET AL., MOLECULAR THERAPY, vol. 18, 2010, pages 1748 - 1757
   CHALLITA ET AL., J. VIROL., vol. 69, no. 2, 1995, pages 748 - 755
   SMITH ET AL., NUCLEIC ACIDS RESEARCH, vol. 26, 1998, pages 4818 - 4827
   LIU ET AL., NATURE BIOTECH., vol. 34, no. 4, April 2016 (2016-04-01), pages 430 - 434
   DE FELIPE, GENETIC VACCINES AND THER., vol. 2, no. 13, 2004
   DE FELIPE ET AL., TRAFFIC, vol. 5, 2004, pages 616 - 626
   SADELAIN ET AL., CANCER DISCOV., vol. 3, no. 4, April 2013 (2013-04-01), pages 388 - 398
   TURTLE ET AL., CURR. OPIN. IMMUNOL., vol. 24, no. 5, October 2012 (2012-10-01), pages 633 - 39
   WU ET AL., CANCER, vol. 18, no. 2, March 2012 (2012-03-01), pages 160 - 75
   KOCHENDERFER ET AL., NATURE REVIEWS CLINICAL ONCOLOGY, vol. 10, 2013, pages 267 - 276
   BRENTJENS ET AL., SCI TRANSL MED, vol. 5, no. 177, 2013
   CARPENTER ET AL., CLIN CANCER RES., vol. 19, no. 8, 2013, pages 2048 - 2060
   LING, N. R. ET AL., LEUCOCYTE TYPING III, 1987, pages 302
   COHEN CJ. ET AL., I MOL. RECOGN., vol. 16, 2003, pages 324 - 332
   CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
   AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
   SCHLUETER, C. J. ET AL., J. MOL. BIOL., vol. 256, 1996, pages 859 - 745
   "Antibody-antigen interactions: Contact analysis and binding site topography", J. MOL. BIOL., vol. 262, pages 732 - 745
   LEFRANC MP ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", DEV COMP IMMUNOL, vol. 27, no. 1, January 2003 (2003-01-01), pages 55 - 77, XP055585227, doi:10.1016/S0145-305X(02)00039-3

DOI:   http://dx.doi.org/10.1016/S0145-305X(02)00039-3
   HONEGGER APLIICKTHUN A: "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J MOL BIOL, vol. 309, no. 3, 8 June 2001 (2001-06-08), pages 657 - 70, XP004626893, doi:10.1006/jmbi.2001.4662

DOI:   http://dx.doi.org/10.1006/jmbi.2001.4662
   MARTIN ET AL.: "Modeling antibody hypervariable loops: a combined algorithm", PNAS, vol. 86, no. 23, 1989, pages 9268 - 9272, XP000165667, doi:10.1073/pnas.86.23.9268

DOI:   http://dx.doi.org/10.1073/pnas.86.23.9268
   SCHULER ET AL.: "SYFPEITHI, Database for Searching and T-Cell Epitope Prediction", IMMUNOINFORMATICS METHODS IN MOLECULAR BIOLOGY, vol. 409, no. 1, 2007, pages 75 - 93
   PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887
   HUDECEK ET AL., CLIN. CANCER RES., vol. 19, 2013, pages 3153
   HUDECEK ET AL., CANCER IMMUNOL RES., vol. 3, no. 2, 2015, pages 125 - 135
   JORES ET AL., PROC. NAT'L ACAD. SCI. U.S.A., vol. 87, 1990, pages 9138
   CHOTHIA ET AL., EMBO J., vol. 7, 1988, pages 3745
   LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55
   KOTB, CLINICAL MICROBIOLOGY REVIEWS, vol. 8, 1995, pages 411 - 426
   JANEWAY ET AL.: "Immunobiology: The Immune System in Health and Disease", vol. 4, 1997, CURRENT BIOLOGY PUBLICATIONS, pages: 33
   KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES
   PARKHURST ET AL., CLIN CANCER RES., vol. 15, 2009, pages 169 - 180
   COHEN ET AL., J IMMUNOL., vol. 175, 2005, pages 5799 - 5808
   VARELA-ROHENA ET AL., NAT MED., vol. 14, 2008, pages 1390 - 1395
   LI, NAT BIOTECHNOL., vol. 23, 2005, pages 349 - 354
   HOLLER ET AL., NAT IMMUNOL, vol. 4, 2003, pages 55 - 62
   HOLLER ET AL., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 5387 - 92
   LI ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 349 - 54
   CHERVIN ET AL., J IMMUNOL METHODS, vol. 339, 2008, pages 175 - 84
   SINGHRAGHAVA, BIOINFORMATICS, vol. 17, no. 12, 2001, pages 1236 - 1237
   SINGHRAGHAVA: "ProPred: prediction of HLA-DR binding sites", BIOINFORMATICS, vol. 17, no. 12, 2001, pages 1236 - 1237, XP002371461, doi:10.1093/bioinformatics/17.12.1236

DOI:   http://dx.doi.org/10.1093/bioinformatics/17.12.1236
   HOO, W. F. ET AL., PNAS (USA, vol. 89, 1992, pages 4759
   WIILFING, C.PLIICKTHUN, A., J. MOL. BIOL., vol. 242, 1994, pages 655
   KURUCZ, I. ET AL., PNAS (USA, vol. 90, 1993, pages 3830
   HACKETT ET AL., MOLECULAR THERAPY: THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 18, 2010, pages 1748 - 1757
   FEDOROV ET AL., SCI. TRANSL. MEDICINE, vol. 5, no. 215, December 2013 (2013-12-01)
   ROSENBERG, NAT REV CLIN ONCOL., vol. 8, no. 10, 2011, pages 577 - 85
   THEMELI ET AL., NAT BIOTECHNOL., vol. 31, no. 10, 2013, pages 928 - 933
   TSUKAHARA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 438, no. 1, 2013, pages 84 - 9
   BENSONBYRD, J. CLIN. ONCOL., vol. 30, no. 16, 2012, pages 2013 - 15
   TAOANDERSON, BONE MARROW RESEARCH, 2011, pages 924058
   CHU ET AL., LEUKEMIA, vol. 28, no. 4, 2013, pages 917 - 27
   GARFALL ET AL., DISCOV MED., vol. 17, no. 91, 2014, pages 37 - 46
   KOCHENDERFER ET AL., J. IMMUNOTHERAPY, vol. 32, no. 7, 2009, pages 689 - 702
   HERMAN ET AL., J. IMMUNOLOGICAL METHODS, vol. 285, no. 1, 2004, pages 25 - 40
   WADWA ET AL., J. DRUG TARGETING, vol. 3, 1995, pages 1 1 1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.